These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 16625145)

  • 1. Refractory anemia in a patient with allergy to intravenous iron drugs.
    Fishbane S
    Kidney Int; 2006 May; 69(10):1910-3. PubMed ID: 16625145
    [No Abstract]   [Full Text] [Related]  

  • 2. Correction of the anemia of epidermolysis bullosa with intravenous iron and erythropoietin.
    Fridge JL; Vichinsky EP
    J Pediatr; 1998 May; 132(5):871-3. PubMed ID: 9602203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poor response to treatment of renal anaemia with erythropoietin corrected by iron given intravenously.
    Macdougall IC; Hutton RD; Cavill I; Coles GA; Williams JD
    BMJ; 1989 Jul; 299(6692):157-8. PubMed ID: 2504356
    [No Abstract]   [Full Text] [Related]  

  • 4. Maintenance therapy with intravenous iron in hemodialysis patients receiving erythropoietin.
    Kotaki M; Uday K; Henriquez M; Blum S; Dave M
    Clin Nephrol; 1997 Jul; 48(1):63-4. PubMed ID: 9247787
    [No Abstract]   [Full Text] [Related]  

  • 5. Combined recombinant human erythropoietin-blood letting strategy for treating anemia and iron overload in hemodialysis patients.
    Agroyannis B; Koutsicos D; Tzanatou-Exarchou H; Varsou-Papadimitriou E; Kapetanaki A; Yatzidis H
    Int J Artif Organs; 1991 Jul; 14(7):403-6. PubMed ID: 1889892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythropoietin--advent of a new treatment.
    Winearls C
    Practitioner; 1987 Oct; 231(1436):1269-73. PubMed ID: 3333088
    [No Abstract]   [Full Text] [Related]  

  • 7. Guide to total dose intravenous iron dextran therapy.
    Hanson DB; Hendeles L
    Am J Hosp Pharm; 1974 Jun; 31(6):592-5. PubMed ID: 4407476
    [No Abstract]   [Full Text] [Related]  

  • 8. Iron dextran treatment in peritoneal dialysis patients on erythropoietin.
    Suh H; Wadhwa NK
    Adv Perit Dial; 1992; 8():464-6. PubMed ID: 1361849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Intravenous iron-dextran versus peroral iron and blood transfusion for anemia].
    Lewinski U; van der Lijn E; Djaldetti M
    Harefuah; 1973 Aug; 85(4):167-9. PubMed ID: 4756186
    [No Abstract]   [Full Text] [Related]  

  • 10. Cardiac hemolysis and anemia refractory to erythropoietin: on anemia in dialysis patients.
    Evers J
    Nephron; 1995; 71(1):108. PubMed ID: 8538832
    [No Abstract]   [Full Text] [Related]  

  • 11. [Hemoglobin production after treatment with iron dextran in total dose infusion compared with oral ferrosuccinate].
    Olsson KS
    Nord Med; 1970 Dec; 84(49):1568. PubMed ID: 5488574
    [No Abstract]   [Full Text] [Related]  

  • 12. [Improvement of the anemia associated with multiple myeloma and renal dysfunction by recombinant human erythropoietin].
    Nakata H; Matsuzaki M; Shimamoto Y; Yamaguchi M
    Rinsho Ketsueki; 1990 Oct; 31(10):1752-3. PubMed ID: 2255069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of intravenous iron on insulin sensitivity in dialysis patients.
    Iliescu EA; White CA; Toffelmire EB; Hudson RW
    Hemodial Int; 2007 Oct; 11(4):492-3. PubMed ID: 17922749
    [No Abstract]   [Full Text] [Related]  

  • 14. Total dose iron infusion.
    Nutr Rev; 1969 Jul; 27(7):193-6. PubMed ID: 4900032
    [No Abstract]   [Full Text] [Related]  

  • 15. [Treatment of anemia in chronically dialyzed patients].
    Moynot A
    Nephrologie; 1998; 19(3):125-7. PubMed ID: 9633055
    [No Abstract]   [Full Text] [Related]  

  • 16. Accelerated total dose infusion of low molecular weight iron dextran is safe and efficacious in chronic kidney disease patients.
    Sinha S; Chiu D; Peebles G; Swoboda P; Kolakkat S; Lamerton E; Fenwick S; Bhandari S; Kalra PA
    QJM; 2011 Mar; 104(3):221-30. PubMed ID: 20956457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Human recombinant erythropoietin (rH-EPO) in chronic hemodialysis patients].
    Jalil R; Vaccarezza A; Jara A; Lira P; Vial S; Serrano V
    Rev Med Chil; 1990 Jun; 118(6):629-34. PubMed ID: 1775783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of anemia with decreasing hepcidin levels following valve replacement for severe tricuspid regurgitation.
    Suzuki T; Hanawa H; Ding L; Ito M; Kashimura T; Obata H; Hu YH; Jiao S; Namura O; Kodama M
    Eur J Haematol; 2012 Jun; 88(6):551-2. PubMed ID: 22420462
    [No Abstract]   [Full Text] [Related]  

  • 19. Correction of serious iron overload in a chronic hemodialysis patient by recombinant human erythropoietin and removal of red blood cells: confirmation by follow-up liver biopsy.
    Onoyama K; Nakamura S; Yamamoto M; Kawadoko T; Nanishi F; Komoda T; Murai K; Fujishima M
    Nephron; 1990; 56(3):325-8. PubMed ID: 2077417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment with low doses of intravenous iron does not modify hemoglobin nor the erythropoietin dosage].
    Fernández-Gallego J; Martín MA; Alonso A; Toledo R
    Nefrologia; 2006; 26(1):143-4. PubMed ID: 16649439
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.